STOCK TITAN

Guardant Health (NASDAQ: GH) insider plans more sales after June disposals

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) received a Rule 144 notice relating to proposed sales of its common stock for the account of officer AmirAli Talasaz. The notice covers up to 37,500 shares, described as founder shares acquired from the issuer on September 22, 2018, with sales to be effected through Stifel Nicolaus & Company Inc. The filing also lists prior sales of Guardant Health common stock by AmirAli Talasaz over the past three months.

Positive

  • None.

Negative

  • None.
Shares to be sold under current notice 37,500 shares of Common Stock Proposed sale by AmirAli Talasaz under Rule 144
Aggregate market value of shares to be sold $6,343,384.00 Value for 37,500 Guardant Health common shares in current notice
Shares outstanding 134,196,170 shares Guardant Health common stock referenced in Rule 144 section
Shares sold on 06/26/2026 116,972 shares Guardant Health common stock sold by AmirAli Talasaz in past 3 months
Proceeds on 06/26/2026 sale $17,638,465.00 Sale of 116,972 Guardant Health shares
Shares sold on 06/29/2026 143,028 shares Guardant Health common stock sold by AmirAli Talasaz in past 3 months
Proceeds on 06/29/2026 sale $21,674,191.00 Sale of 143,028 Guardant Health shares
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
founder shares financial
"Common Stock | 09/22/2018 | Founder Shares | Issuer"
Founder shares are the ownership stakes given to the people who start a company, often with extra voting power or protections compared with ordinary shares. For investors, they matter because founders’ control and incentives influence decisions about strategy, hiring, and whether the company sells or stays independent — like a family that keeps majority voting rights in a household decision. High founder ownership can mean stable leadership but also a risk that outside shareholders have less influence.
aggregate market value financial
"Common Stock | Stifel Nicolaus & Company Inc ... | 6343384.00"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
attorney-in-fact regulatory
"as a duly authorized representative of STIFEL, as attorney-in-fact for AmirAli Talasaz"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing for GH disclose about AmirAli Talasaz’s planned sales?

The Form 144 indicates that AmirAli Talasaz, an officer of Guardant Health (GH), has notified of a proposed sale of up to 37,500 shares of Guardant Health common stock, with the shares to be sold as founder shares acquired from the issuer on September 22, 2018.

How many GH shares are covered by the current Form 144 notice?

The current notice covers up to 37,500 shares of Guardant Health common stock. These are listed as founder shares to be sold through Stifel Nicolaus & Company Inc. on Nasdaq, with an aggregate market value shown as $6,343,384.00.

What prior GH share sales by AmirAli Talasaz are reported in the last 3 months?

The filing reports two prior sales of Guardant Health common stock: 116,972 shares on June 26, 2026 for $17,638,465.00, and 143,028 shares on June 29, 2026 for $21,674,191.00. A remark states shares were sold out of The Talasaz Family Foundation.

What is the aggregate market value of the GH shares proposed to be sold under this Form 144?

The Form 144 lists an aggregate market value of $6,343,384.00 for the 37,500 shares of Guardant Health common stock covered by the current notice, with trading on Nasdaq indicated.

How many Guardant Health (GH) shares are outstanding as referenced in the Form 144?

The Form 144 references 134,196,170 shares of Guardant Health common stock as outstanding. This figure is provided in connection with the Rule 144 securities information section as context for the proposed sale.

Who is executing the planned sale of GH shares for AmirAli Talasaz?

The planned sale of up to 37,500 GH shares is to be executed through Stifel Nicolaus & Company Inc.. The Form 144 is signed by Brian Schneiweiss as a duly authorized representative of Stifel, as attorney-in-fact for AmirAli Talasaz.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature